Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.

Antigny F, Chaumais MC, Humbert M, Montani D.

Fundam Clin Pharmacol. 2019 Aug;33(4):426-427. doi: 10.1111/fcp.12489. Epub 2019 Jun 26. No abstract available.

PMID:
31148228
2.

Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study.

Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, Revol B, Despas F, Montani D, Cracowski JL.

Eur Respir J. 2019 May 9;53(5). pii: 1802472. doi: 10.1183/13993003.02472-2018. Print 2019 May.

PMID:
30846469
3.

Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Chaumais MC, O'Connell C, Savale L, Guignabert C, Perros F, Jaïs X, Sitbon O, Humbert M, Montani D.

Int J Clin Pharm. 2018 Aug;40(4):790-794. doi: 10.1007/s11096-018-0712-y. Epub 2018 Aug 13.

PMID:
30101375
4.

Lorlatinib - Induced pulmonary arterial hypertension.

Chabrol A, Mayenga M, Hamid AM, Friard S, Salvator H, Doubre H, Fraboulet S, Metivier AC, Catherinot E, Rivaud E, Chaumais MC, Montani D, Couderc LJ, Tcherakian C.

Lung Cancer. 2018 Jun;120:60-61. doi: 10.1016/j.lungcan.2018.03.023. Epub 2018 Mar 27.

PMID:
29748016
5.

Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease.

Savale L, Chaumais MC, Dorfmuller P, Humbert M, Montani D.

Presse Med. 2017 Dec;46(12 Pt 1):1223-1225. doi: 10.1016/j.lpm.2017.09.026. Epub 2017 Nov 10. No abstract available.

PMID:
29129416
6.

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul.

7.

Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.

Weatherald J, Chaumais MC, Montani D.

Curr Opin Pulm Med. 2017 Sep;23(5):392-397. doi: 10.1097/MCP.0000000000000412. Review.

PMID:
28639957
8.

Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicentre, cross-sectional study.

Huynh E, Chaumais MC, Sterpu R, Rieutord A, Curatolo N.

J Clin Pharm Ther. 2017 Jun;42(3):372. doi: 10.1111/jcpt.12513. Epub 2017 Mar 8. No abstract available.

PMID:
28276082
9.

[Mitomycin-induced pulmonary veno-occlusive disease: A rare but severe complication].

Montani D, Chaumais MC, Seferian A, Humbert M.

Bull Cancer. 2017 Feb;104(2):202-204. doi: 10.1016/j.bulcan.2016.10.012. Epub 2016 Nov 21. French. No abstract available.

PMID:
27884394
10.

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.

Riou M, Seferian A, Savale L, Chaumais MC, Guignabert C, Canuet M, Magro P, Rea D, Sitbon O, Jaïs X, Humbert M, Montani D.

Eur Respir J. 2016 Nov;48(5):1517-1519. doi: 10.1183/13993003.01410-2016. Epub 2016 Oct 6. No abstract available.

11.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M.

J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2.

12.

Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension.

Savale L, Chaumais MC, Montani D, Jaïs X, Hezode C, Antonini TM, Coilly A, Duclos-Vallée JC, Samuel D, Simonneau G, Humbert M, Sitbon O.

Chest. 2016 Jul;150(1):256-8. doi: 10.1016/j.chest.2016.04.031. No abstract available.

PMID:
27396788
13.

Interferon-induced pulmonary hypertension: an update.

Savale L, Chaumais MC, O'Connell C, Humbert M, Sitbon O.

Curr Opin Pulm Med. 2016 Sep;22(5):415-20. doi: 10.1097/MCP.0000000000000307. Review.

PMID:
27387101
14.

Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model".

Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D.

Circulation. 2016 Apr 5;133(14):e592-3. doi: 10.1161/CIRCULATIONAHA.116.020946. No abstract available. Erratum in: Circulation. 2016 May 10;133(19):e657-8.

PMID:
27045136
15.

Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.

O'Connell C, Amar D, Boucly A, Savale L, Jaïs X, Chaumais MC, Montani D, Humbert M, Simonneau G, Sitbon O.

Drug Saf. 2016 Apr;39(4):287-94. doi: 10.1007/s40264-015-0365-x. Review.

PMID:
26748508
16.

Pulmonary arterial hypertension in patients treated with interferon.

Savale L, Chaumais MC, Sitbon O, Humbert M.

Eur Respir J. 2015 Dec;46(6):1851-3. doi: 10.1183/13993003.01376-2015. No abstract available.

17.

New pharmacotherapy options for pulmonary arterial hypertension.

Perrin S, Chaumais MC, O'Connell C, Amar D, Savale L, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

Expert Opin Pharmacother. 2015;16(14):2113-31. doi: 10.1517/14656566.2015.1074177. Epub 2015 Aug 12. Review.

PMID:
26290279
18.

Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.

Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, Samuel D, Duclos-Vallée JC, Algalarrondo V.

Gastroenterology. 2015 Nov;149(6):1378-1380.e1. doi: 10.1053/j.gastro.2015.07.051. Epub 2015 Aug 4.

PMID:
26253303
19.

Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study.

Perrin S, Montani D, O'Connell C, Günther S, Girerd B, Savale L, Guignabert C, Sitbon O, Simonneau G, Humbert M, Chaumais MC.

Eur Respir J. 2015 Oct;46(4):1211-4. doi: 10.1183/13993003.00051-2015. Epub 2015 Jul 23. No abstract available.

20.

Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.

Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmüller P, Hautefort A, Raymond N, Savale L, Jaïs X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D.

Circulation. 2015 Sep 1;132(9):834-47. doi: 10.1161/CIRCULATIONAHA.115.014207. Epub 2015 Jun 30.

PMID:
26130118
21.

Chemotherapy-induced pulmonary hypertension: role of alkylating agents.

Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, Dumas SJ, Raymond N, Lau E, Savale L, Jaïs X, Sitbon O, Simonneau G, Stenmark K, Cohen-Kaminsky S, Humbert M, Montani D, Perros F.

Am J Pathol. 2015 Feb;185(2):356-71. doi: 10.1016/j.ajpath.2014.10.021. Epub 2014 Dec 11. Review.

PMID:
25497573
22.

Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.

Chaumais MC, Guignabert C, Savale L, Jaïs X, Boucly A, Montani D, Simonneau G, Humbert M, Sitbon O.

Am J Cardiovasc Drugs. 2015 Feb;15(1):13-26. doi: 10.1007/s40256-014-0095-y. Review.

PMID:
25421754
23.

Pulmonary arterial hypertension in patients treated with interferon.

Savale L, Sattler C, Günther S, Montani D, Chaumais MC, Perrin S, Jaïs X, Seferian A, Jovan R, Bulifon S, Parent F, Simonneau G, Humbert M, Sitbon O.

Eur Respir J. 2014 Dec;44(6):1627-34. doi: 10.1183/09031936.00057914. Epub 2014 Oct 16. Erratum in: Eur Respir J. 2015 Dec;46(6):1854.

24.

N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats.

Chaumais MC, Ranchoux B, Montani D, Dorfmüller P, Tu L, Lecerf F, Raymond N, Guignabert C, Price L, Simonneau G, Cohen-Kaminsky S, Humbert M, Perros F.

Respir Res. 2014 Jun 14;15:65. doi: 10.1186/1465-9921-15-65.

25.

Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy.

Montani D, Bertoletti L, Chaumais MC, Perrin S, Fabre D, Chaouat A, Jaïs X, Simonneau G, Humbert M.

Eur Respir Rev. 2014 Jun;23(132):260-3. doi: 10.1183/09059180.00005913. No abstract available.

26.

Targeted therapies in pulmonary arterial hypertension.

Montani D, Chaumais MC, Guignabert C, Günther S, Girerd B, Jaïs X, Algalarrondo V, Price LC, Savale L, Sitbon O, Simonneau G, Humbert M.

Pharmacol Ther. 2014 Feb;141(2):172-91. doi: 10.1016/j.pharmthera.2013.10.002. Epub 2013 Oct 14. Review.

27.

Calcium-channel blockers in pulmonary arterial hypertension.

Chaumais MC, Macari EA, Sitbon O.

Handb Exp Pharmacol. 2013;218:161-75. doi: 10.1007/978-3-642-38664-0_7. Review.

PMID:
24092340
28.

Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

Buenestado A, Chaumais MC, Grassin-Delyle S, Risse PA, Naline E, Longchampt E, Tenor H, Devillier P.

PLoS One. 2013 Sep 16;8(9):e74640. doi: 10.1371/journal.pone.0074640. eCollection 2013.

29.

Drugs induced pulmonary arterial hypertension.

Seferian A, Chaumais MC, Savale L, Günther S, Tubert-Bitter P, Humbert M, Montani D.

Presse Med. 2013 Sep;42(9 Pt 2):e303-10. doi: 10.1016/j.lpm.2013.07.005. Epub 2013 Aug 22. Review.

PMID:
23972547
30.

Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.

Chaumais MC, Perrin S, Sitbon O, Simonneau G, Humbert M, Montani D.

Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1193-205. doi: 10.1517/17425255.2013.804063. Epub 2013 Jun 12. Review.

PMID:
23944387
31.

A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.

Tu L, De Man FS, Girerd B, Huertas A, Chaumais MC, Lecerf F, François C, Perros F, Dorfmüller P, Fadel E, Montani D, Eddahibi S, Humbert M, Guignabert C.

Am J Respir Crit Care Med. 2012 Oct 1;186(7):666-76. doi: 10.1164/rccm.201202-0309OC. Epub 2012 Jul 12.

32.

Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae.

Jacolot A, Judel C, Chaumais MC, Louchahi K, Nicolas P, Marchand S, Petitjean O, Mimoz O.

Chemotherapy. 2012;58(2):129-33. doi: 10.1159/000337061. Epub 2012 May 10.

PMID:
22572147
33.

Pulmonary hypertension associated with benfluorex exposure.

Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, Pison C, Dromer C, Poubeau P, Lamblin N, Habib G, Reynaud-Gaubert M, Bourdin A, Sanchez O, Tubert-Bitter P, Jaïs X, Montani D, Sitbon O, Simonneau G, Humbert M.

Eur Respir J. 2012 Nov;40(5):1164-72. doi: 10.1183/09031936.00188611. Epub 2012 Apr 20.

34.

A study of magnesium deficiency in human and experimental pulmonary hypertension.

Chaumais MC, Lecerf F, Fattal S, Savale L, Günther S, Huertas A, Montani D, Perros F, Humbert M, German-Fattal M.

Magnes Res. 2012 Mar 1;25(1):21-7. doi: 10.1684/mrh.2012.0301.

35.

Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension.

Dorfmüller P, Chaumais MC, Giannakouli M, Durand-Gasselin I, Raymond N, Fadel E, Mercier O, Charlotte F, Montani D, Simonneau G, Humbert M, Perros F.

Respir Res. 2011 Sep 9;12:119. doi: 10.1186/1465-9921-12-119.

36.

[Novel immunopathological approaches to pulmonary arterial hypertension].

Perros F, Montani D, Dorfmüller P, Huertas A, Chaumais MC, Cohen-Kaminsky S, Humbert M.

Presse Med. 2011 Apr;40 Suppl 1:1S3-13. doi: 10.1016/S0755-4982(11)70002-1. Review. French.

PMID:
21536178
37.

Pharmacokinetic evaluation of continuous intravenous epoprostenol.

Chaumais MC, Jobard M, Huertas A, Vignand-Courtin C, Humbert M, Sitbon O, Rieutord A, Montani D.

Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1587-98. doi: 10.1517/17425255.2010.534458. Review.

PMID:
21077785
38.

Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats.

Price LC, Montani D, Tcherakian C, Dorfmüller P, Souza R, Gambaryan N, Chaumais MC, Shao DM, Simonneau G, Howard LS, Adcock IM, Wort SJ, Humbert M, Perros F.

Eur Respir J. 2011 Apr;37(4):813-22. doi: 10.1183/09031936.00028310. Epub 2010 Aug 6.

39.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
40.

Fatal pulmonary fibrosis after rituximab administration.

Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschênes G.

Pediatr Nephrol. 2009 Sep;24(9):1753-5. doi: 10.1007/s00467-009-1195-9. Epub 2009 Apr 25.

PMID:
19396468
41.

Unusual pharmacokinetics of intravitreal and systemic voriconazole in a patient with Scedosporium apiospermum endophthalmitis.

Nochez Y, Arsene S, Le Guellec C, Bastides F, Morange V, Chaumais MC, Pisella PJ.

J Ocul Pharmacol Ther. 2008 Feb;24(1):87-90. doi: 10.1089/jop.2007.0087.

PMID:
18370878

Supplemental Content

Loading ...
Support Center